A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies Download larger version About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through [...]
Phase I/II trial of EP0031, a next generation selective RET inhibitor RET fusions occur in various cancers, and resistance to selpercatinib and pralsetinib, current first generation selective RET inhibitors that are indicated for non-small cell lung cancer and pancreatic cancer, are a growing issue. Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, [...]
Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor [...]
Ellipses updates clinicians at Asco on clinical trial programmes Ellipses Pharma (“Ellipses”), a global company drug development company focused on accelerating innovative cancer medicines and treatments, today announces its leadership team will attend the forthcoming American Society of Oncology (ASCO) conference in Chicago where they will brief clinicians on the progress of clinical and pre-clinical [...]
Ellipses announces FDA clearance of IND application for EP0031 for patients with advanced RET-altered malignancies A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today [...]
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]
Preliminary results from a first-in-human study of EP0042 in patients with R/R AML David Taussig, MRCP, FRCPath, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses preliminary results from an ongoing Phase I/IIa study which is evaluating the safety and tolerability of EP0042, a dual FLT3 and aurora kinase inhibitor, in patients with relapsed/refractory [...]
Expansion of Scientific Affairs Group More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG). Ellipses [...]
Ellipses Pharma features in SCRIP Ellipses Pharma has been featured in SCRIP: READ ARTICLE About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted [...]
